ERA Sciences' Ben O'Brien shares five tips to improve pharma and biotech companies' AI literacy when operating in a GxP environment.
- Here's What Limits AI's Outlook For Replacing Knowledge Workers
- How Much Knowledge Work Can Biopharma Offload To AI? Answer: Not Much
- Tales From The Trenches: Developing Potency Assays Outside Big Pharma
- Is Your Pharma Facility Ready For The Next Public Health Crisis?
- FDA Leading The Decline Of Animal Testing
- A Flexible Mindset For Bridging Between Cell-Based Assay Groups
- Advanced Manufacturing And CDMOs Are Rewriting The CGT Cost Equation
- Exploring Outsourcing's Role In CGT Scalability And Affordability
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Accelerating Bulk Harvest Release Testing With A PCR-Based Solution
Adventitious agent testing is frequently a bottleneck in downstream processing. Discover a PCR-based solution for manufacturing processes using CHO cells and animal origin-free components.
-
Epigenetics Application Guide
To fully understand biology and disease mechanisms, it is crucial to explore the role of epigenetic factors. Explore how epigenetic regulation works and methods to study these essential components.
-
CHO Media Screening Success Using Benchmarking Studies
Explore the challenges of media screening and a straightforward approach for saving time, reducing risks, and improving outcomes.
-
EHR-To-EDC Success In A Complex, Adaptive Platform Trial
I-SPY 2, one of the longest-running adaptive platform trials in oncology, is revolutionizing breast cancer research through a dynamic, data-driven approach to evaluating novel therapies.
-
Compliance With Annex 1- Sterile Fill Finish
Eurofins ensures Annex 1 compliance through robotic isolators, PUPSIT, contamination control strategies, and rigorous training for aseptic sterile fill-finish of early-phase clinical products.
-
Cell Culture Automation Of The 3D Cancer Spheroid Assay
Discover how automated 3D cell culture methods enhance efficiency and consistency in high-throughput drug screening to accelerate the discovery of new anti-cancer therapies.
-
Recommendations For Successful IND Approval Of RNA-LNP Drugs
The existing regulatory system is ambiguous for RNA therapeutics. Leverage this Investigational New Drug (IND) guide to help accelerate and strengthen the process IND filing of novel nanomedicines.
-
The Medicines Of Tomorrow: A Primer On The Gene Editing Landscape
Learn about the distinction between gene therapy and gene editing, as well as the therapeutic potential of CRISPR treatments and the challenges associated with clinical trials and commercialization.
-
Cutting Red Tape: Direct Data Capture In Clinical Trials
Say goodbye to duplicate work in clinical trials. Discover how Direct Data Capture revolutionizes research, benefiting patients, sponsors, and sites while streamlining processes.
-
Understand Fluorescence And How It Enhances Scientific Exploration
Deepen your understanding of fluorescence for research, and gain valuable insight into how to select appropriate fluorophores and fluorescent proteins for your experiments.
NEWSLETTER ARCHIVE
- 07.25.25 -- Unlocking Value In Biopharma Operations: A C-Suite Call To Action
- 07.24.25 -- Essential Steps For A Successful Analytical Tech Transfer
- 07.23.25 -- Redefining CGT With Exosomes And EVs
- 07.22.25 -- Tools For Smarter Antibody Discovery
- 07.22.25 -- STREAM Edition: Meeting Cell Therapy Market Demand

- Redefining CGT With Exosomes And EVs
- Inside AviadoBio And Astellas's Shared Mission To Bring Gene Therapy To Patients With FTD-GRN
- Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More
- Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham
- The Promise Of Focused Ultrasound For AAV Gene Therapy Delivery
CELL AND GENE CONTENT COLLECTIONS

While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections